The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy

Alessandro Rambaldi, Cristina Boschini, Giuseppe Gritti, Federica Delaini, Elena Oldani, Andrea Rossi, Anna Maria Barbui, Daniele Caracciolo, Marco Ladetto, Angela Gueli, Alberto De Crescenzo, Roberto Passera, Liliana Devizzi, Caterina Patti, Alessandro Massimo Gianni, Corrado Tarella

Research output: Contribution to journalArticle

Abstract

The peripheral blood lymphocyte to monocyte ratio (LMR) at diagnosis can be clinically relevant in patients with diffuse large B-cell lymphoma (DLBCL). We reviewed the outcome of 1,057 DLBCL patients followed from 1984 to 2012 at four centers. LMR was analyzed as a clinical biomarker by receiver-operating characteristic (ROC) analysis and Harrell's C-statistics. Patients were characterized by a median age of 61 years, International Prognostic Index (IPI) score of >2 in 39%, and were treated with a rituximab-containing chemotherapy in 66%. LMR proved strongly predictive for survival in patients treated with rituximab-based programs, but not in those receiving chemotherapy alone. Additionally, an LMR value of ≤2.6 (as determined by ROC analysis) was associated with a worst performance status, a higher lactate dehydrogenase (LDH) level, an advanced clinical stage, and a higher IPI score (P=0.000). In patients treated with rituximab-supplemented chemotherapy programs, an LMR value of

Original languageEnglish
Pages (from-to)1062-1067
Number of pages6
JournalAmerican Journal of Hematology
Volume88
Issue number12
DOIs
Publication statusPublished - Dec 2013

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Monocytes
Lymphocytes
Drug Therapy
ROC Curve
L-Lactate Dehydrogenase
Biomarkers
Rituximab
Survival

ASJC Scopus subject areas

  • Hematology

Cite this

The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy. / Rambaldi, Alessandro; Boschini, Cristina; Gritti, Giuseppe; Delaini, Federica; Oldani, Elena; Rossi, Andrea; Barbui, Anna Maria; Caracciolo, Daniele; Ladetto, Marco; Gueli, Angela; De Crescenzo, Alberto; Passera, Roberto; Devizzi, Liliana; Patti, Caterina; Gianni, Alessandro Massimo; Tarella, Corrado.

In: American Journal of Hematology, Vol. 88, No. 12, 12.2013, p. 1062-1067.

Research output: Contribution to journalArticle

Rambaldi, A, Boschini, C, Gritti, G, Delaini, F, Oldani, E, Rossi, A, Barbui, AM, Caracciolo, D, Ladetto, M, Gueli, A, De Crescenzo, A, Passera, R, Devizzi, L, Patti, C, Gianni, AM & Tarella, C 2013, 'The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy', American Journal of Hematology, vol. 88, no. 12, pp. 1062-1067. https://doi.org/10.1002/ajh.23566
Rambaldi, Alessandro ; Boschini, Cristina ; Gritti, Giuseppe ; Delaini, Federica ; Oldani, Elena ; Rossi, Andrea ; Barbui, Anna Maria ; Caracciolo, Daniele ; Ladetto, Marco ; Gueli, Angela ; De Crescenzo, Alberto ; Passera, Roberto ; Devizzi, Liliana ; Patti, Caterina ; Gianni, Alessandro Massimo ; Tarella, Corrado. / The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy. In: American Journal of Hematology. 2013 ; Vol. 88, No. 12. pp. 1062-1067.
@article{424536e0739a47918db6ea213bc6043e,
title = "The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy",
abstract = "The peripheral blood lymphocyte to monocyte ratio (LMR) at diagnosis can be clinically relevant in patients with diffuse large B-cell lymphoma (DLBCL). We reviewed the outcome of 1,057 DLBCL patients followed from 1984 to 2012 at four centers. LMR was analyzed as a clinical biomarker by receiver-operating characteristic (ROC) analysis and Harrell's C-statistics. Patients were characterized by a median age of 61 years, International Prognostic Index (IPI) score of >2 in 39{\%}, and were treated with a rituximab-containing chemotherapy in 66{\%}. LMR proved strongly predictive for survival in patients treated with rituximab-based programs, but not in those receiving chemotherapy alone. Additionally, an LMR value of ≤2.6 (as determined by ROC analysis) was associated with a worst performance status, a higher lactate dehydrogenase (LDH) level, an advanced clinical stage, and a higher IPI score (P=0.000). In patients treated with rituximab-supplemented chemotherapy programs, an LMR value of",
author = "Alessandro Rambaldi and Cristina Boschini and Giuseppe Gritti and Federica Delaini and Elena Oldani and Andrea Rossi and Barbui, {Anna Maria} and Daniele Caracciolo and Marco Ladetto and Angela Gueli and {De Crescenzo}, Alberto and Roberto Passera and Liliana Devizzi and Caterina Patti and Gianni, {Alessandro Massimo} and Corrado Tarella",
year = "2013",
month = "12",
doi = "10.1002/ajh.23566",
language = "English",
volume = "88",
pages = "1062--1067",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "12",

}

TY - JOUR

T1 - The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy

AU - Rambaldi, Alessandro

AU - Boschini, Cristina

AU - Gritti, Giuseppe

AU - Delaini, Federica

AU - Oldani, Elena

AU - Rossi, Andrea

AU - Barbui, Anna Maria

AU - Caracciolo, Daniele

AU - Ladetto, Marco

AU - Gueli, Angela

AU - De Crescenzo, Alberto

AU - Passera, Roberto

AU - Devizzi, Liliana

AU - Patti, Caterina

AU - Gianni, Alessandro Massimo

AU - Tarella, Corrado

PY - 2013/12

Y1 - 2013/12

N2 - The peripheral blood lymphocyte to monocyte ratio (LMR) at diagnosis can be clinically relevant in patients with diffuse large B-cell lymphoma (DLBCL). We reviewed the outcome of 1,057 DLBCL patients followed from 1984 to 2012 at four centers. LMR was analyzed as a clinical biomarker by receiver-operating characteristic (ROC) analysis and Harrell's C-statistics. Patients were characterized by a median age of 61 years, International Prognostic Index (IPI) score of >2 in 39%, and were treated with a rituximab-containing chemotherapy in 66%. LMR proved strongly predictive for survival in patients treated with rituximab-based programs, but not in those receiving chemotherapy alone. Additionally, an LMR value of ≤2.6 (as determined by ROC analysis) was associated with a worst performance status, a higher lactate dehydrogenase (LDH) level, an advanced clinical stage, and a higher IPI score (P=0.000). In patients treated with rituximab-supplemented chemotherapy programs, an LMR value of

AB - The peripheral blood lymphocyte to monocyte ratio (LMR) at diagnosis can be clinically relevant in patients with diffuse large B-cell lymphoma (DLBCL). We reviewed the outcome of 1,057 DLBCL patients followed from 1984 to 2012 at four centers. LMR was analyzed as a clinical biomarker by receiver-operating characteristic (ROC) analysis and Harrell's C-statistics. Patients were characterized by a median age of 61 years, International Prognostic Index (IPI) score of >2 in 39%, and were treated with a rituximab-containing chemotherapy in 66%. LMR proved strongly predictive for survival in patients treated with rituximab-based programs, but not in those receiving chemotherapy alone. Additionally, an LMR value of ≤2.6 (as determined by ROC analysis) was associated with a worst performance status, a higher lactate dehydrogenase (LDH) level, an advanced clinical stage, and a higher IPI score (P=0.000). In patients treated with rituximab-supplemented chemotherapy programs, an LMR value of

UR - http://www.scopus.com/inward/record.url?scp=84888067608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888067608&partnerID=8YFLogxK

U2 - 10.1002/ajh.23566

DO - 10.1002/ajh.23566

M3 - Article

C2 - 23940056

AN - SCOPUS:84888067608

VL - 88

SP - 1062

EP - 1067

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 12

ER -